On: Trial results for new lung cancer drug are 'off the charts'

[andyjohnson0]

Its a side-effect of the naming convention for generic drug naming [1]. Small molecule inhibitors end with “ib”. Monoclonal antibodies end with “mab”. Etc.

[1] https://en.wikipedia.org/wiki/Drug_nomenclature